Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (January 2021)
34 slides from Matinas Biopharma's investor presentation, Jan 14, 2021
Slide 1: Corporate Presentation
MATINAS BIOPHARMA Corporate Presentation \" IOR?621 (NYSE AMER: MTNB)
Slide 2: Forward-Looking Statements
Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other statements t
Slide 3: Company Highlights
Company Highlights LYPDISO™ (mars001) Next Generation Rx Omega-3 = Initial indication in severe hypertriglyceridemia with potential expansion into multi-billion-dollar cardiovascular risk reduction market = Clear differentiation from currently approved prescription omega-3 products, supported by str
Slide 4: LYPDISO Overview
LYPDISO™ (mats001) Overview MATINAS BIOPHARMA
Slide 5: LYPDISO Targets a Significant Market Opportunity
LYPDISO™ Targets a Significant Market Opportunity US Adult Prevalence, Calculated*, 2020 Hypertriglyceridemia 62,750,000 Borderline High (HTG) High (HTG) 150-199 mg/dL 200-499 mg/dL 27,610,000 31,375,000 (44%) (50%) L FUTURE TARGET POPULATIONS | ‘Assuming 250M US adult population ‘Sources: DRG Dysli
Slide 6: The LYPDISO Difference
The LYPDISO™ Difference . OMEGA-3 BENEFITS Prescription Omega-3s offer a rare combination of potency, safety, and affordability Substantial benefits for both patients AND the US healthcare system Potential multi-billion-dollar market in the US (approval of Vascepa to treat patients at CV risk with T
Slide 7: Formulated to Achieve Best-in-Class Potency
Formulated to Achieve Best-in-Class Potency Less Bioavailable Highly Bioavailable ETHYL ESTHERS se FREE FATTY ACIDS ~ LOVAZA * Vascepa'’ Epanova' 6° Lyppiso™ DPA THER OTHER OTHER © 15T GENERATION ° @— 2X2 GENERATION —® Repurposed Products For CV Applications *estimated composition MATINAS BIOPHARMA
Slide 8: LYPDISO Demonstrated Superiority Head-to-Head vs. Vascepa
LyPDISO™ Demonstrated Superiority Head-to-Head vs. Vascepa® TRIGLYCERIDE REDUCTION MEDIAN % CHANGES FROM MEDIAN % CHANGES FROM PRE-TREATMENT (MEDIAN % CHANGE FROM BASELINE) PRE-TREATMENT VALUES FOR LIPIDS FOR APOLIPOPROTEINS AND PCSK9 om i “TET VOC! Non-HOLC HDLC LLC? Tc ABSR! Apo Al? Apo cill PesKe
Slide 9: Substantially Higher EPA Blood Levels vs. Vascepa On Low Fat Diet
Substantially Higher EPA Blood Levels vs. Vascepa® On Low Fat Diet MEAN PLASMA BASELINE-ADJUSTED TOTAL EPA CONCENTRATION ON FINAL DAY OF TREATMENT?* 350 —@-— Lyppisom —@- Vascepa* 300 250 200 150 Plasma Baseline-Adjusted Total EPA (ug/mL) 100 50 Time (Hours) from Dose MATINAS 9 1: T=0 is drug admini
Slide 10: Omega-3s and Outcome Benefits — A Tale of Two Levels (EPA)
Omega-3s and Outcome Benefits — A Tale of Two Levels (EPA)? REDUCE-IT (Vascepa®) STRENGTH (Epanova®) = REDUCE-IT showed an outcome benefit, while STRENGTH was stopped for futility Outcome Benefit(s) Trial Size 13,086 % Primary Prevention % Secondary Prevention = EPA levels were the only fen biomarke
Slide 11: Omega-3s and Outcome Benefits — A Tale of Two Levels (EPA)
Omega-3s and Outcome Benefits — A Tale of Two Levels (EPA)? EPA levels in STRENGTH were significantly lower than in REDUCE-IT and likely not high enough to have any therapeutic effect Median STRENGTH Nicholls S) et al. JAMA 2020 (published on-line) 150 i | | 2 i REDUCE-IT |< <117 > |< 117-191 >|< >1
Slide 12: LYPDISO Clinical Development Plan
LYPDISO™ (mar9001) Clinical Development Plan MATINAS BIOPHARMA
Slide 13: The Path to Significant Market Share
The Path to Significant Market Share 7) REGISTRATION STUDIES ie) LJ Vv 28-day tox study Vv First head-to-head study of LYPDISO™ vs Vascepa® (n=42) v 90-day tox study = Patients with TGs 200-400 mg/dL Vv Phase 1 PK vs Lovaza = 14-day crossover design with 28-day washout Single dose comparative bioava
Slide 14: ENHANCE-IT Study: LYPDISO vs Vascepa
ENHANCE-IT Study: LYPDISO™ vs Vascepa® OBJECTIVES To assess PD effects of LYPDISO™, compared with Vascepa’, on TGs and other lipoprotein z ‘Men and women. lipids, apolipoproteins, hs-CRP, and PCSK9 in men and women with elevated TGs a aa 1 Randomized, open-label, active-control crossover design (n=1
Slide 15: Matinas and FDA Aligned on LYPDISO Phase Program
Matinas and FDA Aligned on LYPDISO™ Phase 3 Program Key Takeaways from End-of-Phase 2 Meeting = Matinas and FDA aligned on all key aspects of Company’s Phase 3 development program = Preclinical tox program and comparative bioavailability study provided acceptable bridge to Lovaza® under 505(b)(2) =
Slide 16: LYPDISO Development Timeline
LYPDISO™ Development Timeline IND Reactivation EOP2 Meeting with FDA , NDA Submission 3023 7 16 MATINAS “BIOPHARMA
Slide 17: Expanding Intellectual Property Portfolio
Expanding Intellectual Property Portfolio 17 PATENT APPLICATIONS Additional IP to be developed as clinical development plan progresses ORANGE BOOK-LISTABLE U.S. PATENTS ISSUED, EXTEND TO 2033 Q4 2014: US Patent No. 8,906,964 Q3 2018: US Patent No. 10,058,521 4 additional U.S. patent applications pen
Slide 18: Lipid NanoCrystal Platform
18 Lipid NanoCrystal Platform Targeted, Well-Tolerated Intracellular Delivery MATINAS BIOPHARMA
Slide 19: LNC Platform Enables a Paradigm-Shift in Intracellular Drug Delivery
LNC Platform Enables a Paradigm-Shift in Intracellular Drug Delivery 19 Matinas’ LNC Platform comprises highly efficient, fusogenic and non-toxic drug formulations FLEXIBLE ADMINISTRATION = Oral = Intravenous = Intramuscular = Intranasal PHYSIOLOGICALLY TARGETS ACTIVATED CELLS No evidence of immunog
Slide 20: LNC Platform Also Enables a Paradigm-Shift in Drug Delivery Pharmacokinetics
LNC Platform Also Enables a Paradigm-Shift in Drug Delivery Pharmacokinetics Traditional Model of Drug Delivery ° Free Drug Cry ©0906 ™s, 0° 0° Ow 7 ° A. ° o osm o o° Fre oi ° © (0, © -o ° 5 i “28 ; -@.: ° > 0 Py @: ° Z Ue ' © 905 an se ° ‘Macrophage ° Elevated drug levels in plasma generally requir
Slide 21: Lipid NanoCrystals are not Liposomes or Lipid Nano-Particles
Lipid NanoCrystals are not Liposomes or Lipid Nano-Particles Liposomes vs. LNCs Liposome Polar Head Group Hydrophobic ACYL Chains Fluid, Pliable Bilayer Internal Aqueous Space Stable Membrane-Resists Fusion Cochleate Cor | $84 OOO £84 OOS 0408 BH oo oe te Rigid, Solid Bilayers No Internal Aqueous Sp
Slide 22: MAT2203 Oral Amphotericin B
MAT2203 Oral Amphotericin B MATINAS BIOPHARMA
Slide 23: Invasive Fungal Infections Represent an Urgent Growing Global Need
Invasive Fungal Infections Represent an Urgent Growing Global Need Global Invasive fungal infection market value in 2018 Potential for significant Amphotericin B market expansion Global Amphotericin B sales in. 2018 Invasive fungal infections are an urgent and largely overlooked global problem due t
Slide 24: MAT2203: A Novel Approach with a Proven Therapeutic
MAT2203: A Novel Approach with a Proven Therapeutic 24 MAT2203 IMPROVED PROFILE BIG POTENTIAL Oral amphotericin B formulation utilizing LNCs Being developed with support from the NIH Proprietary formulation with robust intellectual property protection Potential to expand use into larger prophylaxis
Slide 25: MAT2203: Preclinical Studies in a Mouse Model of Cryptococcal Meningoencephalitis
MAT2203: Preclinical Studies in a Mouse Model of Cryptococcal Meningoencephalitis DIC RFP merge = MAT2203 LNCs tagged with rhodamine and dosed orally = Crypto-positive, MAT2203 treated mice show fluorescence of LNCs at site of crypto infection = Crypto-negative, MAT2203 treated mice show no fluoresc
Slide 26: EnACT Study: Encochleated Oral Amphotericin for Cryptococcal Meningitis
EnACT Study: Encochleated Oral Amphotericin for Cryptococcal Meningitis RATIONALE Traditional amphotericin B given intravenously (IV AMB) has common and substantial toxicities resulting in serious adverse events or patients having to switch medications. MAT2203 has demonstrated oral bioavailability,
Slide 27: Phase 2 in HIV Patients with Cryptococcal Meningitis
: Phase 2 in HIV Patients with Cryptococcal Meningitis COMPLETED INDUCTION THERAPY EARLY MAINTENANCE THERAPY PROTOCOL DETAILS (2 WEEKS) W/MAT2203 (4 WEEKS) = Open-label, sequential-cohort study assessing safety, Cohort 1 IV Ampho . ’ tolerability and efficacy of MAT2203 n=i0 pceys) = Assess MAT2203
Slide 28: MAT2501 Oral Amikacin
MAT2501 Oral Amikacin MATINAS BIOPHARMA
Slide 29: MAT2501: A Better Amikacin
MAT2501: A Better Amikacin MAT2501 IMPROVED PROFILE SIGNIFICANT UNMET NEED 29 Oral, LNC formulation of the broad-spectrum antibiotic Amikacin Initial indication in treatment of non-tuberculosis mycobacterium (NTM) infections Proprietary formulation with robust intellectual property protection Develo
Slide 30: MAT2501: NTM Program Overview
MAT2501: NTM Program Overview Non-Tuberculosis Mycobacterium NTM organisms, widely present in the environment, are a frequent cause of challenging pulmonary infections, especially in patients with pre-existing inflammatory lung diseases such as cystic fibrosis Approximately 40-60% of patients have i
Slide 31: Driving Opportunities for Value-Added Partnerships
Driving Opportunities for Value-Added Partnerships A ll Healthcare Genentech = @©. A Member of the Roche Group THERAPEUTICS 31 J GILEAD We are currently working with multiple strategic and research partners to expand potential successful applications of this LNC technology. In January 2019, we colla
Slide 32: Management and Board of Directors
Management and Board of Directors EXECUTIVE OFFICERS Jerome D. Jabbour Co-Founder, Chief Executive Officer James J. Ferguson Ill, M.D., FACC, FAHA Chief Medical Officer Theresa Matkovits, Ph.D. Chief Development Officer Keith A. Kucinski, CPA, MBA Chief Financial Officer Raphael J. Mannino, Ph.D. Ch
Slide 33: Key Catalysts Supporting Investment Thesis
Key Catalysts Supporting Investment Thesis ENHANCE-IT - Top Phase 3 AMPLIFY study in SHTG Line Data Ar] ORAL ° afiar2203 cf | 9 $3.75M Grant from CF Foundation for Preclinical PK and Tox studies Plnais 4b = Stine Ascending Dose MAT2501 in NTM
Slide 34: Matinas BioPharma
MATINAS BIOPHARMA Corporate Presentation \" (NYSE AMER: MTNB)
Matinas BioPharma Holdings — Investor Presentation (January 2021) on 6ix